Screener
AnaptysBio, Inc. ANAB Biopharma Company — Operating Expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219515
| Line item | Biopharma | Royalty Management | Total |
|---|---|---|---|
| External G&A(3) | 8,721 | 3,398 | 12,119 |
| Internal G&A(2) | 10,135 | 3,948 | 14,083 |
| Total G&A | 18,856 | 7,346 | 26,202 |
| Total operating expenses | 52,811 | 7,382 | 60,193 |
| (Loss) income from operations | (52,811) | 18,174 | (34,637) |
| Interest income | 2,328 | 325 | 2,653 |
| Non-cash interest expense | — | (20,859) | (20,859) |
| Other expense, net | (1) | — | (1) |
Item 1. Consolidated Financial Statements
FAQ
- What is AnaptysBio, Inc.'s biopharma company — operating expenses?
- AnaptysBio, Inc. (ANAB) reported biopharma company — operating expenses of $52.81M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — operating expenses changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — operating expenses increased by 3.0% year-over-year, from $51.28M to $52.81M.
- What does biopharma company — operating expenses mean?
- This metric represents the aggregate of all costs incurred to run the business, primarily consisting of research and development and general administrative expenses. It provides a comprehensive view of the company's total cash burn rate from operations. Tracking this is essential for understanding the company's runway and the capital required to sustain its clinical development programs.
Ask your AI about AnaptysBio, Inc.'s biopharma company — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude